Elanco Expands Commitment to Creating Shared Value, Launches New Initiative Empowering Small-Scale Producers in Sub-Saharan Africa
March 16 2022 - 8:30AM
Business Wire
Elanco Animal Health Incorporated (ELAN: NYSE) today announces
the expansion of its shared value footprint across Sub-Saharan
Africa, delivering on its 2030 pledge to create sustainable
development solutions for those who depend on livestock for their
livelihoods.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220316005069/en/
Raising livestock is important to secure
people's livelihood in Sub-Saharan Africa. (Photo: Business
Wire)
MAHABA (Managing Animal Health and Acaricides for a Better
Africa) is Elanco’s second shared value initiative and aims to
support small-scale producers in Nigeria and Uganda by defining and
implementing strategies to effectively manage tick infestations in
cattle. As the global leader in acaricides, a group of products to
kill ticks and mites in animals, Elanco brings a comprehensive
acaricide portfolio in affordable small pack sizes together with
expertise on tick control to local livestock producers.
Additionally, Elanco commits to bringing its comprehensive product
portfolio for cattle and poultry to Nigeria, opening a new market
for the company.
Livestock farming is an important part of securing the
livelihoods of communities in Sub-Saharan Africa, providing
nutritious food for growing populations and an essential source of
income. Yet, an estimated 80% of cattle in Nigeria and up to 98% of
cattle in Uganda are infested with ticks*, threatening the health
and welfare of animals, decreasing animal productivity and posing a
heavy economic burden on livestock keepers.
“At Elanco, our relentless commitment to making a positive
change in the world is core to our purpose. We are proud to
continue delivering an important contribution to African livestock
communities, improving animal health and food security for local
families. That’s why we are continuing to drive our shared value
blueprint and look forward to expanding our impact on small farming
operations,” said Ramiro Cabral, executive vice president and
president of Elanco International.
Building on the success of Elanco’s first shared value
initiative in East Africa, East Africa Growth Accelerator, the new
initiative will provide local cattle farmers with innovative
solutions that help address current acaricide resistance issues.
Elanco is partnering with GALVmed (Global Alliance for Livestock
Veterinary Medicines), an international not-for profit organization
that works with partners to make livestock vaccines, medicines and
diagnostics accessible to small-scale farmers in developing
countries. The partnership is supported by the Bill & Melinda
Gates Foundation.
“We are excited to collaborate with Elanco to enable access and
proper use of high-quality acaricides and innovative tools that
empower small-scale producers to successfully tackle the impact of
ticks as well as prevent tick-borne diseases. This will help
farmers raise healthier animals, grow their farms’ efficiency and
output and eventually allow them to make better returns on their
investments,” said Carolin Schumacher, chief executive officer at
GALVmed.
Applying acaricides is currently the only viable option to
prevent tick infestations, however, available treatment options are
often unaffordable. Lack of training for the proper use of
prevention products may also lead to resistance or even treatment
failures. Through MAHABA, the partnership brings new means to
control tick infestations, preventing loss of livestock
productivity and making an important contribution to sustainable
food production in the region.
Since 2017, Elanco has been committed to a purpose-driven
business targeting small-scale livestock farmers, creating a
lasting impact on the welfare of local communities in East Africa.
Elanco was recently recognized for this approach being named among
Fortune Magazine’s Top 20 on their Change the World List.
Elanco’s combined shared value footprint is part of Elanco’s
Healthy Purpose™ sustainability and ESG framework and illustrates
the company’s perspective on animals’ role as a solution to two of
society’s greatest challenges – food security and climate
change.
Through its continued engagements with smallholders, Elanco
delivers on its pledge to create more resilient food systems by
2030, helping to improve the efficiency and sustainability of every
farmer the company works with, improve the health and welfare of 3
billion farm animals as well as enhance agricultural productivity
and income of 250,000 small-scale dairy and poultry producers.
*Source: ClinGlobal, data on file.
About Elanco Healthy Purpose™
Elanco is committed to the idea that its business can be a
unique force for good for all in society – starting with animals.
Therefore, its approach to sustainability - called Elanco Healthy
Purpose™ - is a framework of Environmental, Social, and Governance
(ESG) commitments focused on advancing the well-being of animals,
people, and the planet. In this context, Elanco issued three
Healthy Purpose pledges, driving sustainable change and supporting
the United Nations Sustainable Development Goals (SDGs). Learn more
here.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global
leader in animal health dedicated to innovating and delivering
products and services to prevent and treat disease in farm animals
and pets, creating value for farmers, pet owners, veterinarians,
stakeholders, and society as a whole. With nearly 70 years of
animal health heritage, we are committed to helping our customers
improve the health of animals in their care, while also making a
meaningful impact on our local and global communities. At Elanco,
we are driven by our vision of Food and Companionship Enriching
Life and our Elanco Healthy Purpose™ Sustainability/ESG Pledges –
all to advance the health of animals, people, and the planet. Learn
more at www.elanco.com.
ABOUT GALVmed
GALVmed works with partners to make livestock vaccines,
medicines and diagnostics accessible and available to millions of
smallholder farmers in developing countries who depend on livestock
for their livelihood. The international not-for-profit company aims
to make a significant contribution towards transformational change
in the smallholder livestock health landscape by developing a
portfolio of high-impact products and initiating a range of private
sector market initiatives operating at scale in the smallholder
sector in Africa and South Asia. GALVmed is headquartered in
Edinburgh, Scotland with regional offices in Nairobi, Kenya and New
Delhi, India and funded by Bill & Melinda Gates Foundation and
UK aid from the UK Government. Website: www.galvmed.org
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220316005069/en/
Investor Contact: Katy Grissom (317) 273-9248
kathryn.grissom@elancoah.com Media Contact: Colleen Parr Dekker
(317) 989-7011 colleen.dekker@elancoah.com
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Jul 2023 to Jul 2024